adverse events

Incidence of pneumonitis in patients undergoing immunotherapy

Can spinners improve understanding of adverse events in patients with cancer?

irAEs with single-agent PD-1 vs PD-L1 inhibitors

Evaluation of costs associated with AEs in urothelial cancer patients

AdRad safety results: radium-223/VMAT RT in the first-line for metastatic prostate cancer

Adverse events in bladder cancer immunotherapy

Avoiding chemotherapy in the treatment of breast cancer

Optimizing treatment for renal cell carcinoma with sequential therapies

Chemotherapy vs. immunotherapy for the treatment of Merkel cell carcinoma

Improved survival, toxicity & QoL with pembrolizumab in head and neck cancer

VXM01 vaccine in progressive glioblastoma: final results

Can checkpoint inhibitors combinations replace single agent drugs?

Guiding clinicians to recognize toxicity levels of newer immunotherapy agents

Managing the adverse events of immune checkpoint inhibitors

Vinflunine shows a chemotherapeutic advantage for locally-advanced and metastatic penile cancer

Head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic CRPC